MHC Class 1 and PDL-1 Status of Primary Tumor and Lymph Node Metastatic Tumor Tissue in Gastric Cancers by Ibrahim Halil Erdogdu

“…Despite the use of VEGF-, EGFR-, and HER2-targeting agents, prognosis is still poor in advanced gastric cancer. Although cancer immunotherapy responds well in some patients, clinical use is limited due to unanswered patients. …”
Get full text

Oncolytic reprogramming of tumor microenvironment shapes CD4 T-cell memory via the IL6ra-Bcl6 axis for targeted control of glioblastoma by Jeffrey M. Grimes, Sadashib Ghosh, Shamza Manzoor, Li X. Li, Monica M. Moran, Jennifer C. Clements, Sherrie D. Alexander, James M. Markert, Jianmei W. Leavenworth

“…Abstract Oncolytic viruses (OVs) emerge as a promising cancer immunotherapy. However, the temporal impact on tumor cells and the tumor microenvironment, and the nature of anti-tumor immunity post-therapy remain largely unclear. …”
Get full text

Unveiling the role of SYNGR4 in breast cancer development: a novel target for immunotherapy by Jie Ma, Hongtao Wang, Zhengwei Gui, Yuanrong Yang

“…SYNGR4 overexpression affects breast cancer proliferation, migration, and tumor immune infiltration, and promotes breast cancer tumor-associated macrophage polarization toward M2.DiscussionSYNGR4 overexpression can affect the prognosis of breast cancer patients by promoting M2 polarization of tumor-associated macrophages in breast cancer, and this molecule may be a novel target for breast cancer immunotherapy.…”
Get full text

Immunotherapy of Brain Cancers: The Past, the Present, and Future Directions by Lisheng Ge, Neil Hoa, Daniela A. Bota, Josephine Natividad, Andrew Howat, Martin R. Jadus

“…Immunotherapy offers the opportunity to allow the patient's own immune system a chance to help eliminate the cancer. Immunotherapy's strength is that it efficiently treats relatively small tumors in experimental animal models. …”
Get full text

Dual Roles of IL-27 in Cancer Biology and Immunotherapy by Marina Fabbi, Grazia Carbotti, Silvano Ferrini

“…Here, we will summarize IL-27 biological activities and its functional overlaps with the IFNs and discuss its dual role in tumors in the light of potential applications to cancer immunotherapy.…”
Get full text

Q11, a CYP2E1 inhibitor, exerts anti-hepatocellular carcinoma effect by inhibiting M2 macrophage polarization by Cunzhen Zhang, Yan Fang, Mengxue Guo, Liming Tang, Yurong Xing, Jun Zhou, Yuanyuan Guo, Yuhan Gu, Qiang Wen, Na Gao, Haiwei Xu, Hailing Qiao

“…Abstract Despite significant advancements in cancer immunotherapy, many patients continue to respond poorly. …”
Get full text

Elotuzumab Enhances CD16-Independent NK Cell-Mediated Cytotoxicity against Myeloma Cells by Upregulating Several NK Cell-Enhancing Genes by Yan-Hua Wang, Shotaro Hagiwara, Hiroshi Kazama, Yuki Iizuka, Norina Tanaka, Junji Tanaka

“…Combination therapy using antibodies and natural killer (NK) effectors, which are innate immune cells with safe and potent antitumor activity, is a promising approach for cancer immunotherapy and can enhance antitumor effects. Elotuzumab (Elo) is an immune-stimulatory antibody that targets the signaling lymphocytic activation molecule family 7 (SLAMF7) expressed on the surface of MM and NK cells. …”
Get full text

Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy by Amelia C. McCue, Stephen J. Demarest, Karen J. Froning, Michael J. Hickey, Stephen Antonysamy, Brian Kuhlman

“…This study showcases an approach to developing immune-modulating therapeutics that prioritizes safety and has the potential to advance cancer immunotherapy treatment strategies.…”
Get full text

Reprogramming of Melanoma Tumor-Infiltrating Lymphocytes to Induced Pluripotent Stem Cells by Hidehito Saito, Keisuke Okita, Noemi Fusaki, Michael S. Sabel, Alfred E. Chang, Fumito Ito

“…The ability to reprogram TILs containing patient-specific tumor-reactive repertoire might allow the generation of patient- and tumor-specific polyclonal T cells for cancer immunotherapy.…”
Get full text

Diversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLC by Masayuki Shirasawa, Tatsuya Yoshida, Takaji Matsutani, Yuki Takeyasu, Naoko Goto, Shigehiro Yagishita, Shigehisa Kitano, Hiroaki Kuroda, Toyoaki Hida, Takayasu Kurata, Yuichiro Ohe

Get full text

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors by Ichiro Yamauchi, Daisuke Yabe

“…Given the increasing diversity and complexity of cancer immunotherapy, it is essential to vigilantly screen for thyroid irAEs.…”
Get full text

Immunotherapy-associated autoimmune hemolytic anemia by Uqba Khan, Tarik Hadid, Farman Ali, Muhammad Siddique Khurram, Awais Zaka

“…Checkpoint inhibitors have been the forefront of cancer immunotherapy in recent years. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1) pathway are the prototypic checkpoint targets for immunotherapy. …”
Get full text

Recent advances of nanovaccines on cancer theranostics by Xiaobing Yuan, Xiaobing Yuan, Xiaobing Yuan, Tianyou Xu, Mubashir Hussain, Bin Liu, Jianwei Zhu, Jianwei Zhu

“…This paper reviewed the research progress of some nanovaccines in cancer immunotherapy, including polymer nanoparticle vaccine, liposome nanoparticle vaccine, cell-based nanoparticle vaccine, inorganic nanoparticle vaccine, adjuvant and auxiliary work. …”
Get full text

Pan-Cancer Analysis of the Prognostic and Immunotherapeutic Value of PDGFB by Bai Y, Wang X, Wang B

“…We confirmed that PDGFB positively correlated with CD8 and PDL1 expression in lower grade glioma.Conclusion: This study concludes that PDGFB may serve as a potential prognostic marker and a potential targetable pathway in cancer immunotherapy. Overall, the study sheds new light on the role of PDGFB in cancer and highlights its potential clinical significance.Keywords: PDGFB, pan-cancer, prognosis, immune cell infiltration, biomarker…”
Get full text

Pan-cancer analysis of SOX2: Prognostic implications and potential as a therapeutic target in immune checkpoint modulation by Shoukai Yu, Lingmei Qian, Liling Xu, Jun Ma

“…These findings underscore SOX2's potential in regulating immune checkpoints and enhancing cancer immunotherapy.…”
Get full text

Gastric Cancer Mesenchymal Stem Cells Inhibit NK Cell Function through mTOR Signalling to Promote Tumour Growth by Shuwei Guo, Chao Huang, Fengfeng Han, Bin Chen, Ying Ding, Yuanyuan Zhao, Zhihong Chen, Shaodi Wen, Mei Wang, Bo Shen, Wei Zhu

“…The study results revealed that GCMSCs contributed to dysfunctional NK cells involved at least partially in the inhibition of mTOR signalling, suggesting potential directions for NK cell-based cancer immunotherapy.…”
Get full text

Immunoglobulin Gamma-Like Therapeutic Bispecific Antibody Formats for Tumor Therapy by Shixue Chen, Lingling Li, Fan Zhang, Yu Wang, Yi Hu, Lei Zhao

“…Bispecific antibodies (BsAbs) are a sort of dual functional proteins with specific binding to two distinct targets, which have become a focus of interest in antibody engineering and drug development research and have a promising future for wide applications in cancer immunotherapy and autoimmune disease. The key of clinical application and commercial-scale manufacturing of BsAbs is the amenability to assembly and purification of desired heterodimers. …”
Get full text

Glutamine and cancer: metabolism, immune microenvironment, and therapeutic targets by Ding Nan, Weiping Yao, Luanluan Huang, Ruiqi Liu, Xiaoyan Chen, Wenjie Xia, Hailong Sheng, Haibo Zhang, Xiaodong Liang, Yanwei Lu

“…With the encouraging results of cancer immunotherapy in recent years, more investigation into the impact of glutamine metabolism on immune cell function in the cancer microenvironment could lead to the discovery of new targets and therapeutic approaches. …”
Get full text

Immune checkpoint inhibitors-related thyroid dysfunction: influencing factor analysis, prediction model development, and management strategy proposal by Xinya Li, Zaiwei Song, Yixuan Chen, Jingjing Wu, Dan Jiang, Zhen Zhang, Zeyuan Wang, Rongsheng Zhao

“…Conclusion This study offers comprehensive insights into managing ICI-TD, potentially enhancing tailored cancer immunotherapy management.…”
Get full text

Circulating CD3+HLA-DR+ Extracellular Vesicles as a Marker for Th1/Tc1-Type Immune Responses by Ryutaro Oba, Motomichi Isomura, Akira Igarashi, Kinya Nagata

“…The results suggest that these EV subpopulations reflect in vivo activation status of total CD4+, total CD8+, and Th1/Tc1-type T cells, respectively, and may be helpful in T cell-related clinical settings, such as cancer immunotherapy and treatment of chronic infection, autoimmune diseases, and graft-versus-host disease.…”
Get full text